참고문헌
- Baekelandt M, Kristensen G, Nesland J, et al (1999). Clinical significance of apoptosis-Related Factors p53, MDM2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol, 17, 2061-8. https://doi.org/10.1200/JCO.1999.17.7.2061
- Chen S, Chen X, Xiu Y, et al (2015). Inhibition of ovarian epithelial carcinoma tumorigenesis and progression by microRNA 106b mediated through the RhoC pathway. PLoS One, 10, 125714.
- Cho E, Choi Y, Chae S, et al (2006). Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms. Int J Gynecologic Pathol, 16, 1000-6.
- Coward J, Middleton K and Murphy F (2015). New perspectives on targeted therapy in ovarian cancer. Int J Womens Health, 7, 189-203.
- Dogan E, Saygilia U, Tunab B, et al (2005). P53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysis. Gynecologic Oncol, 97, 46-52. https://doi.org/10.1016/j.ygyno.2004.12.053
- Dolfi S, Jager A, Medina D, et al (2014). Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Letters, 350, 52-60. https://doi.org/10.1016/j.canlet.2014.04.009
- Foulkes W, Stamp G, Afzal S, et al (1995). MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer, 72, 883-8. https://doi.org/10.1038/bjc.1995.428
- Gamal el Din A, Badawi M, Abdel Aal Sh, et al (2015). DNA cytometry and nuclear morphometry in ovarian benign, borderline and malignant tumors. Open Access Macedonian J Medical Sci, 3, 537-44. https://doi.org/10.3889/oamjms.2015.104
- Gilks B, Prat J (2009). Ovarian carcinoma pathology and genetics: recent advances. Human Pathol, 40, 1213-23. https://doi.org/10.1016/j.humpath.2009.04.017
- Gyorgy S, Michael J, Suher O, et al (2016). Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J Gynecological Cancer, 26, 43-51. https://doi.org/10.1097/IGC.0000000000000586
- Hav M, Libberecht L, Ferdnande L, et al (2011). MDM2 gene amplification and protein expression in colon carcinoma: Is targeting MDM2 a new therapeutic option? Virchows Archiv, 458, 197-203. https://doi.org/10.1007/s00428-010-1012-7
- Jenkins L, Durell S, Mazur S, et al (2012). P53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis, 33, 1441-9. https://doi.org/10.1093/carcin/bgs145
- Kanthan R, Senger J, Diudea D (2010). Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol, 8, 60. https://doi.org/10.1186/1477-7819-8-60
- Kaspar H and Crum C (2015). The utility of immunohistochemistry in the differential diagnosis of gynecologic disorders. Arch Pathol Lab Med, 139, 39-54. https://doi.org/10.5858/arpa.2014-0057-RA
- Khandakar B, Mathur S, Kumar L, et al (2014). Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Bio Med Res Int, 2014, 401245.
- Kobel M, Kalloger S, Lee S, et al (2013). Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev, 22, 1677 -86. https://doi.org/10.1158/1055-9965.EPI-13-0391
- Lee L (2003). Ovarian tumors: an overview. Atlas Genetics and Cytogenetics Oncol Haematol, 17, 47-52
- Lee H, Park G, Jung J, et al (2005). Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecological Cancer, 15, 453-61. https://doi.org/10.1111/j.1525-1438.2005.15308.x
- Ma Y, Guan T, Yao H, et al (2013). The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211controls. PLoS One, 8, 55019. https://doi.org/10.1371/journal.pone.0055019
- Manfredi J (2010). The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev, 24, 1580-9. https://doi.org/10.1101/gad.1941710
- Mir R, Tortosa A, Martinez-Soler F, et al (2013). Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer, 132, 1525-36. https://doi.org/10.1002/ijc.27832
- Miyamoto M, Takano M, Iwaya K, et al (2015). Hightemperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers. Br J Cancer, 112, 739-44. https://doi.org/10.1038/bjc.2015.1
- Mokhtar N, Gouda I, Adel I (2007). Malignant female genital system tumors. In 'Cancer Pathology Registry and Time Trend Analysis 2003-2004'. NCI, 77-9.
- Nag S, Zhang X, Srivenugopal K, et al (2014). Targeting MDM2-p53 interaction for cancer therapy: are we there yet? Curr Med Chem, 21, 553-74. https://doi.org/10.2174/09298673113206660325
- Ono K, Tanaka T and Tsunoda T (2000). Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res, 60, 5007-11.
- Palazzo J, Monzon F and Burke M (2000). Overexpression of P21WAF1/OCIP1 and MDM2 characterize serous borderline ovarian tumors. Human Pathol, 31, 698-704. https://doi.org/10.1053/hupa.2000.7641
- Park E, Choi K, Yoo Y, et al (2013). Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation. Anticancer Drugs, 24, 260-9. https://doi.org/10.1097/CAD.0b013e32835c0311
- Rayburn E, Zhang R and He J (2005). MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Current Cancer Drug Targets, 5, 27-41. https://doi.org/10.2174/1568009053332636
- Salim E, Morimura K, Menesi A, et al (2008). Elevated oxidative stress and DNA damage and repair levels in urinary bladder carcinomas associated with Schistosomiasis. Int J Cancer, 123, 601-8. https://doi.org/10.1002/ijc.23547
- Skomedal H, Kristensen G, Abeler V, et al (1997). TP53 protein accumulation and gene mutation in relation to over expression of MDM2 protein in ovarian borderline tumors and stage I carcinomas. J Pathol, 181, 158-65. https://doi.org/10.1002/(SICI)1096-9896(199702)181:2<158::AID-PATH742>3.0.CO;2-8
- Soussi T, Beroud C and Assessing T (2001). P53 status in human tumors to evaluate clinical outcome. Nature Reviews Cancer, 1, 233-44. https://doi.org/10.1038/35106009
- Tachibana M, Watanabe J, Matsushima J, et al (2003). Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma, and related proteins. Int J Gynecological Pathol, 13, 598-606. https://doi.org/10.1046/j.1525-1438.2003.13391.x
- Tuna B, Lebe B, Sis B, et al (2004). MDM2 gene expression in adipose- tissue tumors: association with tumor progression in liposarcomas. Aegean Pathol J, 1, 11-8.
- Tuna B, Yorukoglu K, Tuzel E, et al (2003). Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathology - Res Practice, 199, 323-28. https://doi.org/10.1078/0344-0338-00424
- Turbin D, Cheang M, Bajdik C, et al (2006). MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathol, 19, 69-74. https://doi.org/10.1038/modpathol.3800484
- Uhrinova S, Uhrin D, Powers H, et al (2005). Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Molecular Biol, 350, 587-98. https://doi.org/10.1016/j.jmb.2005.05.010
- Wang A, Guo C, Sun Y, et al (2015). Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas. J Cancer, 6, 542-7. https://doi.org/10.7150/jca.11420
- Wang X, Ongkeko W, Lau A, et al (2001). A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res, 61, 1589-603.
- Wong K, Izaguirre D, Kwan S, et al (2013). Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol, 130, 565-9. https://doi.org/10.1016/j.ygyno.2013.06.016
- Zhang Q, Zeng S and Lu H (2014). Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem, 85, 281-319.